“Three in four Americans have never had their homes tested for radon, and over half say they’re not concerned about their radon exposure, according to a new survey.”
Terminal cancer to cancer-free: ‘Lungs in a box’ technology saves Kentucky man’s life
“(LEX 18) — April is recognized as National Donate Life Month, a time to appreciate those who have given the gift of life and an opportunity to highlight the need for organ donations.”
New Guideline Recommends Chemotherapy With Immunotherapy in Advanced SCLC
“Updated guidelines acknowledge that patients with advanced small cell lung cancer (SCLC) receiving chemotherapy plus immunotherapy followed by maintenance immunotherapy have longer-term survival than those receiving chemotherapy alone. However, this approach does not apply to patients with an EGFR mutation. In addition, guidelines include the use of lurbinectedin (Zepzelca) in the second line for relapsed SCLC. These updates were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.”
Efficacy of acupuncture for cough-related symptom clusters in patients with lung cancer: A randomized controlled trial
“Highlights- Acupuncture is becoming a complementary therapy to cough management. Acupuncture can relieve the cough of lung cancer patients. Acupuncture can not relieve expectoration and shortness of breath.
Durvalumab Confirmed Beneficial After NSCLC Chemoradiotherapy
“The benefits of durvalumab have been confirmed in a new analysis that compared patient characteristics, treatment patterns, and outcomes between those who initiated adjuvant treatment with the anti–PD-L1 antibody after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) and patients who completed their CRT and did not subsequently receive durvalumab.”
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.”
Liposomal Irinotecan Produces Similar PFS, OS as Topotecan in SCLC
“Liposomal irinotecan produced similar survival results as topotecan when used as second-line therapy in patients with small cell lung cancer (SCLC), according to research published in the Journal of Clinical Oncology. Progression-free survival (PFS) and overall survival (OS) were similar with the 2 treatments, but liposomal irinotecan produced a higher response rate and was associated with less toxicity than topotecan.”
New Clinical Study Identifies Personalized Treatment Options for Metastatic Non-Small Cell Lung Cancer With Plasma Proteome Testing
“FORT MYERS, Fla., April 25, 2024 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC).”
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
“QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy. Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC. Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types.”
Study from Phoenix Children’s Research Institute Reveals New Way to Prevent Lung Cancer from Spreading
“PHOENIX , April 25, 2024 /PRNewswire/ — Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix shows normalizing cancer tumor vessels and alleviating low oxygen levels in the tumor microenvironment can improve the effectiveness of chemotherapy treatment in lung cancer, according to a paper published in EMBO Molecular Medicine.”
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
“SHANGHAI, April 24, 2024 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.”
Tislelizumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer
“Combination therapy with the anti-PD-1 monoclonal antibody tislelizumab (Tevimbra) and chemotherapy delivered statistically significant improvements over placebo as a first-line treatment option for patients with extensive-stage small cell lung cancer (ES-SCLC), according to data from the phase 3 RATIONALE-312 study (NCT04005716).”
H.R.6693 – Lung Cancer Screening and Prevention Act of 2023
Sign up to get alerts!
Video:
The Benefit of Perioperative Immunotherapy in Lung Cancer Treatment
“At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, Memorial Sloan-Kettering Cancer Center, New York, New York, argued in favor of perioperative immunotherapy in the treatment of lung cancer.”
Systemic Treatment Options for Non-Small Cell Lung Cancer
“Christine Bestvina, MD, presents her treatment strategy for a 62-year-old female with NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then assesses clinical data, including the MARIPOSA trial, to guide their treatment decisions.”
